Kirk M. Maxey
16Patents
3h-index
17Co-inventors
57Inventor score
Filing activity: Dec 29, 1980 → Jun 9, 2021
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US4352760A | Organic compounds substituted heptadeca-5,9- and 5,10-dienoic acid | Chemistry; Metallurgy | 13 | Expired |
| US9180116B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | Human Necessities | 6 | Active |
| US9487478B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | Human Necessities | 4 | Active |
| US7674921B2 | Internal 1,15-lactones of fluprostenol and related prostaglandin F2α analogs and their use in the treatment of glaucoma and intraocular hypertension | Chemistry; Metallurgy | 2 | Active |
| US7727730B2 | Methods and kits for detection of thromboxane A2 metabolites | Physics | 2 | Active |
| US7358275B2 | Internal 1,15-lactones of fluprostenol and related prostaglandin F2a analogs and their use in the treatment of glaucoma and intraocular hypertension | Chemistry; Metallurgy | 1 | Expired |
| US7972406B2 | Diesel particulate filter and method of making | Performing Operations; Transporting | 1 | Active |
| US8168400B2 | Methods and kits for detection of thromboxane A2 metabolites | Physics | 0 | Active |
| US10556862B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | Human Necessities | 0 | Active |
| US8105790B2 | Methods and kits for detection of thromboxane A2 metabolites | Physics | 0 | Active |
| US7585889B2 | Internal 1,15-lactones of fluprostenol and related prostaglandin F2α analogs and their use in the treatment of glaucoma and intraocular hypertension | Chemistry; Metallurgy | 0 | Active |
| US8063240B2 | Prostaglandin E1 and E2 analogs for the treatment of various medical conditions | Human Necessities | 0 | Active |
| US9676712B2 | Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | Chemistry; Metallurgy | 0 | Active |
| US11066361B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | Human Necessities | 0 | Active |
| US9688627B2 | Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | Chemistry; Metallurgy | 0 | Active |
| US11884624B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.